Anika Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
Anika Therapeutics, Inc. (ANIK) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $31.42 per share as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-03-03
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $31.42.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $31.45; Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed $31.65.
- 2025-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $31.83.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $32.07.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2025-12-31 | $31.42 10-K · filed 2026-03-03 | |
| 2025-06-30 | $31.45 10-Q · filed 2025-11-05 | $31.65 10-Q · filed 2025-07-30 |
| 2025-03-31 | $31.83 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $32.07 10-K · filed 2025-03-17 | |
| 2024-09-30 | $31.92 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $32.05 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $32.41 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $33.42 10-K · filed 2024-03-15 | |
| 2023-09-30 | $33.84 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $33.84 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $33.95 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $34.93 10-K · filed 2023-03-16 | |
| 2022-09-30 | $35.21 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $35.53 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $36.59 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $39.56 10-K · filed 2022-03-11 | |
| 2021-09-30 | $39.65 10-Q · filed 2021-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |